SHANDONG BAILONG CHUANGYUAN BIO-TECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.31 CNY | +1.19% |
|
+3.42% | -7.33% |
| Feb. 27 | Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Bailong Chuangyuan Bio-tech to Build 452 Million Yuan Thai Factory | MT |
| Sales 2024 * | 1.39B 191M | Sales 2025 * | 1.67B 230M | Capitalization | 6.54B 902M |
|---|---|---|---|---|---|
| Net income 2024 * | 341M 47.06M | Net income 2025 * | 408M 56.31M | EV / Sales 2024 * | 4.72 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.92 x |
| P/E ratio 2024 * |
19.2
x | P/E ratio 2025 * |
16
x | Employees | 659 |
| Yield 2024 * |
0.11% | Yield 2025 * |
0.15% | Free-Float | 30.29% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.19% | ||
| 1 week | +3.42% | ||
| Current month | +6.99% | ||
| 1 month | +7.52% | ||
| 3 months | -4.85% | ||
| 6 months | -10.17% | ||
| Current year | -7.33% |
1 week
24.96
26.50
1 month
23.9126.50
Current year
22.5830.33
1 year
19.3730.49
3 years
12.3030.49
5 years
8.9530.49
10 years
8.9530.49
| Managers | Title | Age | Since |
|---|---|---|---|
Hong Jian Zhuo
CEO | Chief Executive Officer | 46 | 08-05-31 |
Bao De Dou
FOU | Founder | 60 | 05-12-29 |
Li Li
DFI | Director of Finance/CFO | 46 | 10-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dan Zheng
BRD | Director/Board Member | 59 | 22-09-18 |
Xia Jiang
BRD | Director/Board Member | 59 | 16-09-24 |
Wan Qing Zheng
BRD | Director/Board Member | 62 | 16-09-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 26.31 | +1.19% | 686,664 |
| 24-04-25 | 26 | -0.88% | 531,060 |
| 24-04-24 | 26.23 | +2.22% | 689,016 |
| 24-04-23 | 25.66 | -0.35% | 494,400 |
| 24-04-22 | 25.75 | +1.22% | 903,128 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
Shandong Bailong Chuangyuan Bio-Tech Co Ltd is a China-based company mainly engaged in food additives. The Company's main businesses include prebiotic series products, mainly including fructooligosaccharides, isomalt oligosaccharides, galacto-oligosaccharides, xylo-oligosaccharides; dietary fiber series products, mainly including resistant dextrin and polydextrose; other starch sugar (alcohol) products, mainly including maltitol, fructose syrup, and maltose syrup; and healthy sweetener products, mainly for the research and development, production and sales of allulose. The Company's main products are widely used in food, dairy products, infant milk powder, functional beverages, health care products, medicine, animal nutrition and feed industries.
Sector
Food Processing
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
26.31
CNY
Average target price
33
CNY
Spread / Average Target
+25.43%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.33% | 902M | |
| -7.96% | 2.85B | |
| -4.03% | 1.9B | |
| +1.44% | 1.84B | |
| -0.45% | 1.17B | |
| -4.77% | 1.15B | |
| +5.63% | 956M | |
| -4.79% | 945M | |
| -1.91% | 780M | |
| -9.76% | 728M |
- Stock Market
- Equities
- 605016 Stock
